Antileishmanial Effects of Synthetic EhPIb Analogs Derived from the Entamoeba histolytica Lipopeptidephosphoglycan

With an estimated number of new cases annually of approximately 1.4 million, leishmaniasis belongs to the most important parasitic diseases in the world. Nevertheless, existing drugs against leishmaniasis in general have several drawbacks that urgently necessitate new drug development. A glycolipid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Fehling, Helena, Choy, Siew Ling, Ting, Frederic, Landschulze, Dirk, Bernin, Hannah, Lender, Sarah Corinna, Mühlenpfordt, Melina, Bifeld, Eugenia, Eick, Julia, Marggraff, Claudia, Kottmayr, Nadine, Groneberg, Marie, Hoenow, Stefan, Sellau, Julie, Clos, Joachim, Meier, Chris, Lotter, Hannelore
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2020
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318009/
https://ncbi.nlm.nih.gov/pubmed/32393489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00161-20
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados